carbamates has been researched along with Acquired Immunodeficiency Syndrome in 23 studies
Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amprenavir is an HIV-1 protease inhibitor which is hepatically metabolized (>80%) with a low renal elimination." | 5.34 | [Pharmacokinetics of amprenavir in HIV-1 patients with renal insufficiency]. ( Deray, G; Izzedine, H; Janus, N; Karie, S; Launay-Vacher, V; Laville, I, 2007) |
| "Amprenavir is an HIV-1 protease inhibitor which is hepatically metabolized (>80%) with a low renal elimination." | 1.34 | [Pharmacokinetics of amprenavir in HIV-1 patients with renal insufficiency]. ( Deray, G; Izzedine, H; Janus, N; Karie, S; Launay-Vacher, V; Laville, I, 2007) |
| "Fosamprenavir 700 mg bid was then added to the regimen, and pharmacokinetic sampling was repeated for all 3 agents at day 11." | 1.32 | Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. ( Back, D; Boffito, M; Dickinson, L; Fletcher, C; Gazzard, B; Higgs, C; Hill, A; Moyle, G; Nelson, M; Pozniak, A, 2004) |
| " Progress is also highlighted about dosing regimens, antiretroviral resistance, and reconstitution of the immune system." | 1.30 | Moving forward: a treatment overview from the 12th World AIDS Conference. ( Agosto, M, 1998) |
| " Each drug trial demonstrates the relationship between dosing and resistance; patients are advised to adhere completely to dosing instructions." | 1.29 | Protease inhibitors and prevention of cross resistance. ( Levin, J, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.35) | 18.7374 |
| 1990's | 8 (34.78) | 18.2507 |
| 2000's | 12 (52.17) | 29.6817 |
| 2010's | 1 (4.35) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Balagopal, A | 1 |
| Smeaton, LM | 1 |
| Quinn, J | 1 |
| Venuto, CS | 1 |
| Morse, GD | 1 |
| Vu, V | 1 |
| Alston-Smith, B | 1 |
| Cohen, DE | 1 |
| Santana-Bagur, JL | 1 |
| Anthony, DD | 1 |
| Sulkowski, MS | 1 |
| Wyles, DL | 1 |
| Talal, AH | 1 |
| Abbasi, NR | 1 |
| Wang, N | 1 |
| ROBISON, JM | 1 |
| Gallant, JE | 1 |
| Bates, SM | 1 |
| Page, KB | 1 |
| Nakielny, RA | 1 |
| Talbot, MD | 1 |
| Basso, S | 1 |
| Solas, C | 1 |
| Quinson, AM | 1 |
| Ravaux, I | 1 |
| Poizot-Martin, I | 1 |
| Bacconier, J | 1 |
| Durand, A | 1 |
| Lacarelle, B | 1 |
| Boffito, M | 1 |
| Dickinson, L | 1 |
| Hill, A | 1 |
| Back, D | 1 |
| Moyle, G | 1 |
| Nelson, M | 1 |
| Higgs, C | 1 |
| Fletcher, C | 1 |
| Gazzard, B | 1 |
| Pozniak, A | 1 |
| Janus, N | 1 |
| Launay-Vacher, V | 1 |
| Izzedine, H | 1 |
| Karie, S | 1 |
| Laville, I | 1 |
| Deray, G | 1 |
| Livington, DJ | 1 |
| Pazhanisamy, S | 1 |
| Porter, DJ | 1 |
| Partaledis, JA | 1 |
| Tung, RD | 1 |
| Painter, GR | 1 |
| Gracia Jones, S | 1 |
| Baggett, TH | 1 |
| Roca, B | 1 |
| Tomás, G | 1 |
| Climent, A | 1 |
| Tomasselli, AG | 1 |
| Heinrikson, RL | 1 |
| Koch, CA | 1 |
| Wolkersdoerfer, G | 1 |
| Kost, RG | 1 |
| Hurley, A | 1 |
| Zhang, L | 1 |
| Vesanen, M | 1 |
| Talal, A | 1 |
| Furlan, S | 1 |
| Caldwell, P | 1 |
| Johnson, J | 1 |
| Smiley, L | 1 |
| Ho, D | 1 |
| Markowitz, M | 1 |
| Levin, J | 1 |
| Agosto, M | 1 |
| Bart, PA | 1 |
| Rizzardi, PG | 1 |
| Gallant, S | 1 |
| Golay, KP | 1 |
| Baumann, P | 1 |
| Pantaleo, G | 1 |
| Eap, CB | 1 |
| Gallant, DM | 1 |
| Head-Dunham, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Continued Salvage Anti-Retroviral Therapy With Abacavir, Amprenavir, and Efavirenz[NCT00001758] | Phase 2 | 25 participants | Interventional | 1997-11-30 | Completed | ||
| Pharmacokinetic Interactions Between Ritonavir, Amprenavir and Efavirenz and Nelfinavir, Amprenavir, and Efavirenz in People Infected With HIV[NCT00001766] | Phase 1 | 22 participants | Interventional | 1998-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for carbamates and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Clinical update: new drugs for HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Che | 1999 |
Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Binding Sites; Carbamates; Clinical Trials as T | 2000 |
3 trials available for carbamates and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy.
Topics: 2-Naphthylamine; Acquired Immunodeficiency Syndrome; Adult; Anilides; Antiviral Agents; Carbamates; | 2020 |
Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; Anti-HIV Agents; Carbamates; CD4 L | 2001 |
Protease inhibitor trial started.
Topics: Acquired Immunodeficiency Syndrome; Adult; Carbamates; Furans; HIV Protease Inhibitors; Humans; Indi | 1998 |
18 other studies available for carbamates and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Cobicistat + elvitegravir + emtricitabine + tenofovir. Two new drugs, but no progress.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; | 2013 |
Doxorubicin-induced hyperpigmentation.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antineoplastic Agents; Antiretroviral Th | 2008 |
A pressure splint which aids in closing an oral antralalveolar fistula.
Topics: Acquired Immunodeficiency Syndrome; Carbamates; Fistula; Humans; Oral Fistula; Organometallic Compou | 1947 |
New antiretroviral agents.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; | 2001 |
Cushing's syndrome mimicking lipodystrophy syndrome in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Carbamates; Cushing Syndrome; Diagnosis, | 2002 |
Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Carbamates; Drug Interactions; Female; F | 2002 |
[Potent new protease inhibitor. Boostered protease inhibitors--a separate class of drugs].
Topics: Acquired Immunodeficiency Syndrome; Carbamates; Clinical Trials as Topic; Dose-Response Relationship | 2003 |
[No selection of mutations. 908 raises genetic resistance barrier].
Topics: Acquired Immunodeficiency Syndrome; Carbamates; DNA Mutational Analysis; Drug Resistance, Multiple, | 2003 |
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Area Under Curve; Carbamates; Drug Administration S | 2004 |
[Pharmacokinetics of amprenavir in HIV-1 patients with renal insufficiency].
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Carbamates; Female; Furans; Humans; Kidn | 2007 |
Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Blood; Blood Proteins; Carbamates; Ca | 1995 |
Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Blood; Blood Proteins; Carbamates; Ca | 1995 |
Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Blood; Blood Proteins; Carbamates; Ca | 1995 |
Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Blood; Blood Proteins; Carbamates; Ca | 1995 |
Stevens-Johnson syndrome after exposure to a pesticide in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Carbamates; Dichlorvos; Humans; Male; Pesticides; Stevens | 1999 |
[Hyperlipoproteineumia in HIV patients undergoing antiretroviral therapy: which risk is greater--pancreatitis or coronary disease?].
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Anti-HIV Agents; Carbamates; Coronary Disease; Di | 2000 |
Abacavir (1592) with protease inhibitors in potent antiretroviral activity.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drug Therapy, C | 1998 |
Protease inhibitors and prevention of cross resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Carbamates; Didanosine; Drug Resistance, Micro | 1995 |
Moving forward: a treatment overview from the 12th World AIDS Conference.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; | 1998 |
Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir.
Topics: Acquired Immunodeficiency Syndrome; Analgesics, Opioid; Carbamates; Dideoxynucleosides; Drug Interac | 2001 |
Antabuse (disulfiram) and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Alcoholism; Aldehyde Dehydrogenase; Carbamates; CD4-Positive T-L | 1991 |